ECSP16097355A - Métodos para el tratamiento de infecciones de virus de la hepatitis b y hepatitis d - Google Patents
Métodos para el tratamiento de infecciones de virus de la hepatitis b y hepatitis dInfo
- Publication number
- ECSP16097355A ECSP16097355A ECIEPI201697355A ECPI201697355A ECSP16097355A EC SP16097355 A ECSP16097355 A EC SP16097355A EC IEPI201697355 A ECIEPI201697355 A EC IEPI201697355A EC PI201697355 A ECPI201697355 A EC PI201697355A EC SP16097355 A ECSP16097355 A EC SP16097355A
- Authority
- EC
- Ecuador
- Prior art keywords
- hepatitis
- treatment
- virus
- methods
- virus infections
- Prior art date
Links
- 241000700721 Hepatitis B virus Species 0.000 title abstract 2
- 241000724709 Hepatitis delta virus Species 0.000 title abstract 2
- 208000037262 Hepatitis delta Diseases 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 title 1
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000003322 Coinfection Diseases 0.000 abstract 1
- 108700024845 Hepatitis B virus P Proteins 0.000 abstract 1
- 229940123066 Polymerase inhibitor Drugs 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000002777 nucleoside Substances 0.000 abstract 1
- 150000003833 nucleoside derivatives Chemical class 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- -1 phosphorothioate nucleic acid Chemical class 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Abstract
Se describe un método para tratar la infección por el virus de la hepatitis B o el virus de la hepatitis B/co-infección del virus de la hepatitis delta, el método comprende administrar a un sujeto que necesite dicho tratamiento un primer agente farmacéuticamente aceptable que comprende al menos un polímero de ácido nucleico fosforotioato y un segundo agente farmacéuticamente aceptable que comprende al menos un nucleósido/nucleótido análogo inhibidor de la polimerasa HBV.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462022846P | 2014-07-10 | 2014-07-10 | |
| US201462091943P | 2014-12-15 | 2014-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP16097355A true ECSP16097355A (es) | 2017-03-31 |
Family
ID=55063440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201697355A ECSP16097355A (es) | 2014-07-10 | 2017-01-03 | Métodos para el tratamiento de infecciones de virus de la hepatitis b y hepatitis d |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9603865B2 (es) |
| EP (1) | EP3166615B1 (es) |
| JP (2) | JP2017521433A (es) |
| KR (2) | KR20170029577A (es) |
| CN (2) | CN106659730A (es) |
| AU (1) | AU2015286199B2 (es) |
| BR (1) | BR112017000320B1 (es) |
| CA (1) | CA2954182C (es) |
| CL (1) | CL2017000008A1 (es) |
| CU (1) | CU20170001A7 (es) |
| DK (1) | DK3166615T3 (es) |
| DO (1) | DOP2017000002A (es) |
| EA (1) | EA036745B1 (es) |
| EC (1) | ECSP16097355A (es) |
| ES (1) | ES2963814T3 (es) |
| FI (1) | FI3166615T3 (es) |
| HK (1) | HK1231402A1 (es) |
| HR (1) | HRP20231400T1 (es) |
| HU (1) | HUE064449T2 (es) |
| IL (1) | IL249660B (es) |
| LT (1) | LT3166615T (es) |
| MD (1) | MD4760C8 (es) |
| MX (1) | MX381042B (es) |
| MY (1) | MY178087A (es) |
| PH (1) | PH12017500010B1 (es) |
| PL (1) | PL3166615T3 (es) |
| PT (1) | PT3166615T (es) |
| RS (1) | RS64833B1 (es) |
| SG (1) | SG11201700073PA (es) |
| SI (1) | SI3166615T1 (es) |
| SM (1) | SMT202300380T1 (es) |
| TW (1) | TWI766831B (es) |
| WO (1) | WO2016004525A1 (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11166976B2 (en) * | 2018-11-08 | 2021-11-09 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| AU2019376079A1 (en) * | 2018-11-08 | 2021-05-27 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2021119325A1 (en) * | 2019-12-12 | 2021-06-17 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| CN112010905B (zh) * | 2020-05-07 | 2021-09-03 | 西安新通药物研究股份有限公司 | 甲磺酸帕拉德福韦晶型及其应用 |
| WO2021223398A1 (zh) * | 2020-05-07 | 2021-11-11 | 西安新通药物研究股份有限公司 | 治疗肝病的晶型及其应用 |
| CN114057816B (zh) * | 2020-07-30 | 2025-02-11 | 浙江柏拉阿图医药科技有限公司 | 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用 |
| WO2022109129A1 (en) * | 2020-11-20 | 2022-05-27 | Aligos Therapeutics, Inc. | Conjugates of s-antigen transport inhibiting oligonucleotide polymers having enhanced liver targeting |
| TW202245809A (zh) | 2020-12-18 | 2022-12-01 | 美商詹森藥物公司 | 用於治療b型肝炎病毒感染之組合療法 |
| WO2022152869A1 (en) | 2021-01-15 | 2022-07-21 | Janssen Sciences Ireland Unlimited Company | Use of oligonucleotides for individuals with hepatic impairment |
| WO2022261046A1 (en) * | 2021-06-07 | 2022-12-15 | Antios Therapeutics, Inc. | Compositions and methods of treating hepatitis d and hepatitis b/hepatitis d co-infections with phosphoramidate clevudine prodrugs |
| WO2023281434A1 (en) | 2021-07-09 | 2023-01-12 | Janssen Pharmaceuticals, Inc. | Use of oligonucleotides for individuals with renal impairment |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5482836A (en) * | 1993-01-14 | 1996-01-09 | The Regents Of The University Of California | DNA purification by triplex-affinity capture and affinity capture electrophoresis |
| BR0314236A (pt) | 2002-09-13 | 2005-08-09 | Replicor Inc | Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos |
| WO2006091798A2 (en) * | 2005-02-22 | 2006-08-31 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Vaccines and methods for prevention and treatment of drug-resistant hiv-1 and hepatitis b virus |
| KR101606495B1 (ko) | 2010-08-20 | 2016-03-28 | 레플리코르 인코포레이티드 | 올리고뉴클레오타이드 킬레이트 복합체 |
| WO2012058210A1 (en) * | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
| WO2012075114A2 (en) * | 2010-12-01 | 2012-06-07 | Ablitech, Inc. | Nucleic acid-polymer conjugates and uses thereof |
| HRP20210840T1 (hr) * | 2012-05-18 | 2021-08-06 | Replicor Inc. | Kompozicije oligonukleotidni helatni kompleks-polipeptid i postupci |
| AR091065A1 (es) * | 2012-05-18 | 2014-12-30 | Replicor Inc | Una formulacion farmaceutica que comprende un quelato de oligonucleotidos antiviral para el tratamiento de una infeccion antiviral |
| BR112015003985A2 (pt) * | 2012-08-30 | 2017-08-08 | Replicor Inc | métodos para tratamento de infecções de hepatite b e hepatite d |
-
2015
- 2015-07-07 HU HUE15818148A patent/HUE064449T2/hu unknown
- 2015-07-07 EP EP15818148.7A patent/EP3166615B1/en active Active
- 2015-07-07 CN CN201580037179.0A patent/CN106659730A/zh active Pending
- 2015-07-07 AU AU2015286199A patent/AU2015286199B2/en not_active Ceased
- 2015-07-07 WO PCT/CA2015/050626 patent/WO2016004525A1/en not_active Ceased
- 2015-07-07 PL PL15818148.7T patent/PL3166615T3/pl unknown
- 2015-07-07 KR KR1020177003538A patent/KR20170029577A/ko not_active Ceased
- 2015-07-07 SM SM20230380T patent/SMT202300380T1/it unknown
- 2015-07-07 PH PH1/2017/500010A patent/PH12017500010B1/en unknown
- 2015-07-07 HK HK17105180.0A patent/HK1231402A1/zh unknown
- 2015-07-07 JP JP2017501004A patent/JP2017521433A/ja active Pending
- 2015-07-07 SI SI201531976T patent/SI3166615T1/sl unknown
- 2015-07-07 MD MDA20170014A patent/MD4760C8/ro active IP Right Grant
- 2015-07-07 BR BR112017000320-1A patent/BR112017000320B1/pt not_active IP Right Cessation
- 2015-07-07 KR KR1020237015821A patent/KR102734495B1/ko active Active
- 2015-07-07 PT PT158181487T patent/PT3166615T/pt unknown
- 2015-07-07 ES ES15818148T patent/ES2963814T3/es active Active
- 2015-07-07 FI FIEP15818148.7T patent/FI3166615T3/fi active
- 2015-07-07 MX MX2017000053A patent/MX381042B/es unknown
- 2015-07-07 MY MYPI2017700005A patent/MY178087A/en unknown
- 2015-07-07 RS RS20231031A patent/RS64833B1/sr unknown
- 2015-07-07 CN CN202111146395.2A patent/CN113750112A/zh active Pending
- 2015-07-07 EA EA201790160A patent/EA036745B1/ru unknown
- 2015-07-07 HR HRP20231400TT patent/HRP20231400T1/hr unknown
- 2015-07-07 SG SG11201700073PA patent/SG11201700073PA/en unknown
- 2015-07-07 DK DK15818148.7T patent/DK3166615T3/da active
- 2015-07-07 CA CA2954182A patent/CA2954182C/en active Active
- 2015-07-07 LT LTEPPCT/CA2015/050626T patent/LT3166615T/lt unknown
- 2015-07-08 US US14/794,129 patent/US9603865B2/en not_active Expired - Fee Related
- 2015-07-13 TW TW104122636A patent/TWI766831B/zh active
-
2016
- 2016-12-20 IL IL249660A patent/IL249660B/en unknown
-
2017
- 2017-01-03 EC ECIEPI201697355A patent/ECSP16097355A/es unknown
- 2017-01-03 DO DO2017000002A patent/DOP2017000002A/es unknown
- 2017-01-03 CL CL2017000008A patent/CL2017000008A1/es unknown
- 2017-01-05 CU CUP2017000001A patent/CU20170001A7/es unknown
-
2020
- 2020-04-20 JP JP2020074639A patent/JP6922030B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP16097355A (es) | Métodos para el tratamiento de infecciones de virus de la hepatitis b y hepatitis d | |
| ECSP15007345A (es) | Métodos para el tratamiento de infecciones de hepatitis b y hepatitis d | |
| MX2017016425A (es) | Terapia con desoxinucleosidos para enfermedades generadas por grupos de nucleotidos desequilibrados, inclusive sindromes de agotamiento del adn mitocondrial. | |
| WO2017191258A8 (en) | INFLUENZA MRNA VACCINES | |
| CO2017004290A2 (es) | Composiciones y métodos para el silenciamiento de la expresión génica del virus de la hepatitis b | |
| HK1248278A1 (zh) | 用於使乙型肝炎病毒基因表达沉默的组合物及方法 | |
| UY35732A (es) | Composiciones terapéuticas de nucleótidos y nucleósidos y usos relacionados con las mismas | |
| LT3512863T (lt) | 2'-pakeistieji-n6-pakeistieji purino nukleotidai, skirti gydymui rnr virusu | |
| MX373703B (es) | Derivados de azepano y metodos para tratar infecciones por hepatitis b. | |
| MX421406B (es) | Composiciones de acido ribonucleico de interferencia (arni) contra el virus de la hepatitis b (hbv) y metodos de uso de estas | |
| EA201790597A1 (ru) | Способы лечения вирусных инфекций filoviridae | |
| CL2016000493A1 (es) | Inhibidores de polimerasa hcv. | |
| MX377531B (es) | Terapia de combinación de un inhibidor del ensamble de la cápside del hbv y un interferón. | |
| EA201290993A1 (ru) | Нуклеозидфосфорамидаты | |
| WO2016183366A3 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
| HK1251010A1 (zh) | 用於治疗乙型肝炎病毒(hbv)感染的试剂及用途 | |
| MX2018003290A (es) | Medios para el tratamiento del vih. | |
| AR106057A1 (es) | Composición con efecto antiviral, composición farmacéutica | |
| CL2017001160A1 (es) | Combinación de composiciones de acción prolongada y métodos para la hepatitis c | |
| AR101126A1 (es) | Composiciones para el tratamiento de infecciones por virus de hepatitis b y hepatitis d | |
| PH12018502320A1 (en) | Reagents for treatment of hepatitis b virus (hbv) infection and use thereof | |
| EA202191771A1 (ru) | КОМПОЗИЦИИ НА ОСНОВЕ RNAi ПРОТИВ ВИРУСА ГЕПАТИТА В (HBV) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| NZ727583B2 (en) | Methods for the treatment of hepatitis b and hepatitis d virus infections | |
| AR105532A1 (es) | Composiciones y métodos para silenciar la expresión génica del virus de la hepatitis b | |
| RU2014143385A (ru) | Способы воздействия на экспрессию гена TP53 |